Infliximab for the treatment of pouchitis
- PMID: 24303499
- PMCID: PMC3845959
- DOI: 10.12998/wjcc.v1.i6.191
Infliximab for the treatment of pouchitis
Abstract
Pouchitis is not a rare complication that develops after an ileal-pouch anastomosis, performed after colectomy in patients refractory to treatment or with complicated ulcerative colitis. This condition may become chronic and unresponsive to medical therapies, including corticosteroids, antibiotics and probiotics. The advent of biological therapies (tumor necrosis factor-α inhibitors) has changed the course of these complications. In particular, in these cases, infliximab (IFX) may represent a safe and effective therapy in order to avoid the subsequent operation for a permanent ileostomy. This article reviews the therapeutic effects of one of the most widely used anti-tumor necrosis factor-α molecules, IFX, for the treatment of complicated pouchitis (refractory to conventional treatment and/or fistulizing).
Keywords: Ileal pouch-anal anastomosis; Infliximab; Pouchitis; Tumor necrosis factor-α; Ulcerative colitis.
References
-
- Langholz E, Munkholm P, Davidsen M, Binder V. Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology. 1992;103:1444–1451. - PubMed
-
- Dozois RR, Kelly KA. The surgical management of ulcerative colitis. In: Kirsner JB, ed , editors. Inflammatory Bowel Disease, 5th edn. Philadelphia: W.B. Saunders; 2000. pp. 626–657.
-
- Meagher AP, Farouk R, Dozois RR, Kelly KA, Pemberton JH. J ileal pouch-anal anastomosis for chronic ulcerative colitis: complications and long-term outcome in 1310 patients. Br J Surg. 1998;85:800–803. - PubMed
-
- Pardi DS, Sandborn WJ. Systematic review: the management of pouchitis. Aliment Pharmacol Ther. 2006;23:1087–1096. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources